A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer
Authors
Hamilton, E. P.Oliveira, M.
Banerji, U.
Hernando, C.
Garcia-Corbacho, J.
Armstrong, Anne C
Ciruelos, E.
Patel, M. R.
Incorvati, J.
Twelves, C.
Brier, T.
Carroll, D.
Fox, S.
Klinowska, T.
Lindemann, J. P. O.
Mather, R.
Maudsley, R.
McGuinness, S.
Sykes, A.
Baird, R.
Affiliation
Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TNIssue Date
2020